Krka Logo

Krka

Develops and sells generic prescription, non-prescription, and animal health products globally.

KRKG | LJSE

Overview

Corporate Details

ISIN(s):
SI0031102120
LEI:
549300H9RLRTRTLRUZ73
Country:
Slovenia
Address:
Šmarješka cesta 006, 8501 Novo mesto
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Krka is a leading international generic pharmaceutical company focused on the development, production, marketing, and sale of human and animal health products. With over 70 years of experience, the company's core business is providing high-quality and innovative generic medicines. Its portfolio is composed of three main segments: prescription pharmaceuticals for treating common diseases, non-prescription products for minor illnesses and preventative care, and a range of animal health products. Krka's products are marketed globally, serving patients in more than 70 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
English 110.6 KB
2025-12-01 08:30
Transaction in Own Shares
Terminski načrt programa odkupa lastnih delnic v prvem polletju 2026
Slovene 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 111.8 KB
2025-12-01 08:30
Transaction in Own Shares
Share buy-back programme schedule from January to June 2026
English 1.5 KB
2025-12-01 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.3 KB
2025-12-01 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.3 KB
2025-12-01 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 118.8 KB
2025-12-01 08:30
Transaction in Own Shares
Pridobivanje lastnih delnic
Slovene 2.1 KB
2025-12-01 08:30
Report Publication Announcement
Financial Calendar 2026
English 69.6 KB
2025-12-01 08:30
Report Publication Announcement
Financial calendar for 2026
English 1.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar 2026
Slovene 104.0 KB
2025-12-01 08:30
Report Publication Announcement
Finančni koledar za leto 2026
Slovene 1.1 KB
2025-11-24 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 122.6 KB
2025-11-24 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.2 KB
2025-11-24 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 119.2 KB

Automate Your Workflow. Get a real-time feed of all Krka filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Krka

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Krka via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

JW LIFESCIENCE CORPORATION Logo
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea
234080
JW PHARMACEUTICAL Logo
South Korea
001060
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.